Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Studies find existing and experimental drugs active against MERS-coronavirus

20.05.2014

A series of research articles published ahead of print in the journal Antimicrobial Agents and Chemotherapy have identified a number of existing pharmaceutical drugs and compounds under development that may offer effective therapies against Middle East Respiratory Syndrome (MERS).

In the first study, researchers screened a library of 290 pharmaceutical drugs, either FDA-approved or in advanced clinical development for antiviral activity against the MERS coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV) in cell culture. They found 27 compounds that were active against both viruses including some cancer drugs and antipsychotics.

"Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to the normal paradigm of huge library screening against a specific viral enzyme," says author Matthew Frieman of the University of Maryland Medical School. "Given development times and manufacturing requirements for new products, repurposing of existing drugs is likely the best solution to rapidly identify therapeutics for outbreaks due to emerging viruses."

Researchers from the National Institutes of Health, the United States Army Medical Research Institute of Infectious Diseases and Zalicus Inc., Cambridge MA, were also involved in the study. A copy of the manuscript can be found online at http://bit.ly/asmtip0514e.

In the second study, researchers collaborating in the European antiviral research program SILVER used a similar methodology to screen a library of 348 FDA-approved drugs for anti-MERS-CoV activity in cell culture. They identified four compounds that inhibited MERS-CoV, SARS-CoV and Human Coronavirus 229E at relatively low concentrations. Two of the compounds were also identified by the U.S. study: the antimalarial drug chloroquine and the antipsychotic chlorpromazine.

"Although their therapeutic potential (alone or in combination) remains to be assessed in animal models, our findings may offer a starting point for treatment of patients infected with zoonotic coronaviruses like MERS-CoV," says corresponding author Eric Snijder of Leiden University Medical Center, the Netherlands. Researchers from the Rega Institute for Medical Research in Leuven, Belgium and the Erasmus Medical Center in Rotterdam, the Netherlands were also involved in the study.

A copy of the manuscript can be found online at http://bit.ly/asmtip0514f.

The third and final study finds that an experimental compound, previously shown to block SARS-CoV replication, can inhibit replication of two other coronaviruses, MERS-CoV and mouse hepatitis virus.

"This study shows that it is possible to target multiple coronaviruses through broad-spectrum inhibitors," says corresponding author Stefan Sarafianos of the Bond Life Sciences Center at the University of Missouri, an author on the study. "This compound could serve as a lead for the development of effective broad-spectrum anti-coronavirus drugs."

###

Researchers from the University of Maryland Medical School and the University of Pennsylvania School of Medicine also contributed to the research. The manuscript can be found online at http://bit.ly/asmtip0514g.

Antimicrobial Agents and Chemotherapy is a publication of the American Society for Microbiology (ASM). The ASM is the largest single life science society, composed of over 39,000 scientists and health professionals. Its mission is to advance the microbiological sciences as a vehicle for understanding life processes and to apply and communicate this knowledge for the improvement of health and environmental and economic well-being worldwide.

Jim Sliwa | Eurek Alert!

Further reports about: ASM MERS-CoV Medical SARS-CoV activity antiviral coronavirus drugs viruses

More articles from Studies and Analyses:

nachricht Video games could dramatically streamline education research
19.09.2014 | Washington State University

nachricht Glucose substitution prolongs lifespan of old mice with short telomeres
18.09.2014 | Leibniz-Institut für Altersforschung - Fritz-Lipmann-Institut e.V. (FLI)

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

"Start-ups and spin-offs funding – Public and private policies", 14th October 2014

12.09.2014 | Event News

BALTIC 2014: Baltic Sea Geologists meet in Warnemünde

03.09.2014 | Event News

IT security in the digital society

27.08.2014 | Event News

 
Latest News

Smallest possible diamonds form ultra-thin nanothreads

22.09.2014 | Materials Sciences

Uncovering the Forbidden Side of Molecules

22.09.2014 | Life Sciences

No sedative necessary: Scientists discover new “sleep node” in the brain

19.09.2014 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>